Viatris (VTRS) Operating Income (2020 - 2026)
Viatris (VTRS) posted quarterly Operating Income of -$79.7 million for Q1 2026, up 97.23% year-over-year from -$40.4 million in Q1 2025, and up 58.64% quarter-over-quarter from -$192.7 million in Q4 2025.
Viatris (VTRS) Operating Income (2020 - 2026) Analysis & Trends
Viatris' Operating Income history runs 7 years deep, the most recent figure standing at -$79.7 million for Q1 2026.
- In Q1 2026, Operating Income rose 97.23% year-over-year to -$79.7 million; the TTM figure through Mar 2026 stood at $139.4 million (up 104.53% YoY), while the FY2025 annual figure was -$2.7 billion, down 26467.33% from the prior year.
- Operating Income for Q1 2026 stood at -$79.7 million, up from -$192.7 million in the prior quarter.
- The five-year high for Operating Income was $707.4 million in Q1 2022, with the low at -$2.9 billion in Q1 2025.
- The 5-year median for Operating Income is $203.9 million (2024), against an average of -$20.7 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income jumped 1247.91% in 2022, then tumbled 1513.54% in 2025.
- Viatris' Operating Income stood at -$201.3 million in 2022, then plunged by 125.78% to -$454.5 million in 2023, then jumped by 60.44% to -$179.8 million in 2024, then slipped by 7.17% to -$192.7 million in 2025, then jumped by 58.64% to -$79.7 million in 2026.
- Business Quant data shows VTRS's Operating Income at -$79.7 million in Q1 2026, -$192.7 million in Q4 2025, and $178.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 18.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.30 Mn |
| Mar 31, 2026 | -79.70 Mn |
| Dec 31, 2025 | -192.70 Mn |
| Sep 30, 2025 | 178.80 Mn |
| Jun 30, 2025 | 233.00 Mn |
| Mar 31, 2025 | -2.88 Bn |
| Dec 31, 2024 | -179.80 Mn |
| Sep 30, 2024 | 225.90 Mn |
| Jun 30, 2024 | -239.90 Mn |
| Mar 31, 2024 | 203.90 Mn |
| Dec 31, 2023 | -454.50 Mn |
| Sep 30, 2023 | 451.70 Mn |
| Jun 30, 2023 | 369.20 Mn |
| Mar 31, 2023 | 399.80 Mn |
| Dec 31, 2022 | -201.30 Mn |
| Sep 30, 2022 | 560.10 Mn |
| Jun 30, 2022 | 548.70 Mn |
| Mar 31, 2022 | 707.40 Mn |
| Dec 31, 2021 | -77.60 Mn |
| Sep 30, 2021 | 357.60 Mn |